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Recently, we generated two bacterial recombinant proteins expressing 89 amino acids of the C-terminal
domain of the Plasmodium vivax merozoite surface protein-1 and the hexa-histidine tag (His6MSP119). One of
these recombinant proteins contained also the amino acid sequence of the universal pan allelic T-cell epitope
(His6MSP119-PADRE). In the present study, we evaluated the immunogenic properties of these antigens when
administered via the intra-nasal route in the presence of distinct adjuvant formulations. We found that C57BL/
6 mice immunized with either recombinant proteins in the presence of the adjuvants cholera toxin (CT) or the
Escherichia coli heat labile toxin (LT) developed high and long lasting titers of specific serum antibodies. The
induced immune responses reached maximum levels after three immunizing doses with a prevailing IgG1 sub-
class response. In contrast, mice immunized by intranasal route with His6MSP119-PADRE in the presence of the
synthetic oligonucleotides adjuvant CpG ODN 1826 developed lower antibody titers but when combined to CT,
CpG addition resulted in enhanced IgG responses characterized by lower IgG1 levels. Considering the limita-
tions of antigens formulations that can be used in humans, mucosal adjuvants can be a reliable alternative for
the development of new strategies of immunization using recombinant proteins of P. vivax.
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Plasmodium vivax causes more than 40 million
cases of malaria every year and an effective vaccine is
greatly needed (reviewed by Mendis et al. 2001). Be-
cause in vitro large-scale cultures of P. vivax will prob-
ably not be available soon, a vaccine will have to be de-
veloped using recombinant DNA technology. The use of
recombinant proteins to generate effective vaccines
faces several challenges such as the limited number of
adjuvants that can be used in humans. Based on that need,
this field is evolving rapidly and a number of clinically
acceptable adjuvant formulations have been described
(reviewed by Singh & O’Hagan 1999, 2002). Many of
these adjuvants perform better than alum, the most used
adjuvant licensed for human use. These new adjuvants
are in most cases used by the parenteral route of immu-
nization. However, some of them can also be used effi-
ciently by the mucosal route including synthetic oligo-
nucleotides containing unmethylated CpG motifs (CpG
ODN) and bacterial toxins such as cholera toxin (CT)
and the heat-labile toxin (LT) produced by some ente-
rotoxigenic Escherichia coli (ETEC) strains (reviewed
by Holmgren et al. 2003). As an alternative administra-
tion route, mucosal-delivered vaccines offer several ad-
vantages over those injected by parenteral routes includ-
ing the lack of iatrogenic infection risks, simple and pain-
less administration, and induction of both systemic and
secreted immune responses (Holmgren et al. 2005,
Holmgren & Czerkinsky 2006).
Recently, we generated two recombinant proteins con-
taining 89 amino acids of the C-terminal region of the P.
vivax merozoite surface protein-1 (MSP119) and the hexa-
histidine tag (His6). The first recombinant protein was
named His6MSP119. The second protein contained the
amino acid sequence of the universal pan allelic T-cell
epitope (PADRE) in addition to the His6MSP119 and was
denominated His6MSP119-PADRE (Cunha et al. 2001).
Both recombinant proteins were recognized by IgG anti-
bodies from individuals recently exposed to P. vivax ma-
laria suggesting that the presence of PADRE did not modify
the epitopes of MSP119 recognized by human IgG (Cunha
et al. 2001, Rodrigues et al. 2003).
The immunogenic properties of these recombinant
proteins were studied by the parenteral immunization of
C57BL/6 mice with formulations containing different
adjuvants (Rosa et al. 2004). Mice developed high anti-
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body titers when immunized with either recombinant
proteins emulsified in complete/incomplete Freund’s
adjuvant (CFA/IFA). Other adjuvants such as MPL/TDM
and CpG ODN 1826 required the presence of the PA-
DRE for maximal and long lasting antibody responses
(Rosa et al. 2004). These results clearly indicated that
immune responses induced by the universal T-cell
epitope PADRE improved adjuvant-assisted immune re-
sponse in the presence of specific adjuvant.
Based on these results, it was our intention to extend
our studies on the immunogenicity of these recombi-
nant proteins to establish whether mucosal adjuvants
could be used to generate immune responses in mice.
To address this question, we compared the serum anti-
body responses elicited by C57BL/6 mice immunized
with vaccine formulations prepared with the
His6MSP119-PADRE or His6MSP119 antigens and deliv-
ered via the intranasal route in the presence of the mu-
cosal adjuvants CpG ODN 1826, CT and/or LT.
MATERIALS AND METHODS
Recombinant proteins containing P. vivax MSP119
- The recombinant proteins were obtained exactly as de-
scribed previously (Cunha et al. 2001). Purified proteins
were analyzed by SDS-PAGE and stained with Coomassie
blue or silver nitrate. A single band of 19 kDa was ob-
served. Protein concentration was determined by absor-
bance according to the following formula:
Concentration (mg/ml) = absorbance 280 nm × ε280 nm/
                              molecular weight
ε280 nm = (number of tryptophan × 5690) +
                  (number of tyrosine × 1280)
Immunization of mice with the recombinant proteins
His6MSP119- PADRE or His6MSP119. - Six to eight-
week-old female C57BL/6 (H-2b) mice were purchased
from Federal University of São Paulo, Brazil. Experi-
ments were performed with approved consent of the
Committee of Ethics of Universidade Federal de São
Paulo-Escola Paulista de Medicina. Groups of six mice
were immunized three times, two weeks apart, with 10
µg of recombinant protein in the presence of 2.5 µg of
CT (Sigma-Aldrich), or 2.5 µg of LT and/or 10 µg of
CpG ODN 1826 (TCCATGACGTTCCTGACGTT) syn-
thesized with a nuclease-resistant phosphorothioate back-
bone (Coley Pharmaceutical Group) as adjuvants. LT was
purified by affinity chromatography as previously de-
scribed (Lasaro et al. 2006) from the 25A-1 ETEC strain
(O78:H12 LT-I/ST CFA/I+) isolated from a diarrheic
child in São Paulo city and kindly supplied by Dr BEC
Guth at the Federal University of São Paulo. Mice were
immunized subcutaneously (s.c.) in the two hind foot-
pads with the recombinant antigen mixed with adjuvant
in a final volume of 50 µl in each footpad, or intrana-
sally (i.n.), drop by drop, assisted by a micropipette for
a final volume of 8 µl in each nostril. For the s.c. immu-
nizations, the second and third doses were administered
at the base of the tail in a 100 µl volume.
Immunological assays - Antibodies to MSP119 in the
mice sera were detected by ELISA essentially as de-
scribed by Cunha et al. (2001). The antigen added to the
plates was the recombinant protein His6-MSP119 (200
ng/well) and the secondary antibody, conjugated to per-
oxidase, was goat anti-mouse IgG (KPL) diluted 1:4000.
Each serum was analyzed in serial dilutions from 1:100
up to 1:1,638,400. The individual titers were considered
as the highest dilution of serum that presented an OD492
higher than 0.1. The results are presented as the log 10
antibody titer of each immunized mouse.
Detection of IgG subclass responses was performed
as described above, except that the secondary antibod-
ies were specific for mouse IgG1, IgG2b, and IgG2c (all
obtained from Southern Technologies) diluted 1:2,000.
The results are presented as the mean of log antibody
titers ± SD of three animals per group.
The affinities of anti-His6MSP119 antibodies were
assessed by a thiocyanate elution-based ELISA (Rosa et
al. 2004). The procedure was similar to that described
for the standard ELISA with the inclusion of an extra step.
After the plates were washed following incubation of the
pooled serum dilutions (1:20,000), ammonium thiocy-
anate, diluted in PBS, was added to the wells in duplicate
or triplicate, in concentrations ranging from 0 to 8M.
The plates were allowed to stand for 15 min at room
temperature before they were washed and the assay pro-
ceeded. The concentration of ammonium thiocyanate re-
quired to dissociate 50% of the bound antibody was deter-
mined. The percentage of binding was calculated as fol-
lows: OD492 in the presence of ammonium thiocyanate
X100/OD492 in the absence of ammonium thiocyanate.
Statistical analysis - The One-Way ANOVA, Stu-
dents’ t test and the Tukey HSD test were used to com-
pare the possible differences between the mean values
of the different groups.
RESULTS
In the presence of the adjuvants CT, LT or CpG ODN
1826, C57BL/6 female i.n. immunized with His6MSP119-
PADRE or His6MSP119 induced high serum IgG titers.
In all cases, maximal antibody responses were detected
after the third immunizing dose (Fig. 1A). In contrast,
i.n. administration of three doses of His6MSP119-PA-
DRE or His6MSP119 in the absence of adjuvant failed to
induce detectable specific antibody responses (Fig. 1A).
Statistical comparison of the different mouse groups
revealed that the antibody titers of mice immunized with
His6MSP119-PADRE or His6MSP119 in the presence of
CT or LT were similar after the third dose (P > 0.05). In
both groups, we found significantly higher specific anti-
body titers to His6MSP119 when compared to animals
immunized with His6MSP119-PADRE admixed with CpG
ODN 1826 (P < 0.01). In addition, mice immunized via
the s.c. route with His6MSP119-PADRE in the presence
of CpG ODN 1826 developed higher serum antibody ti-
ters than those immunized with the same vaccine for-
mulation by the i.n. route (P < 0.05) (Fig. 1A).
Two other vaccine regimens were also tested using
the antigen His6MSP119-PADRE. First, we administered
CT and CpG ODN 1826 together with the antigen by the
i.n. route. This immunization induced similar levels of
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specific antibodies obtained when we used only CT as
adjuvant (P > 0.05). In a different immunization regi-
men, mice were first s.c. primed with the antigen ad-
mixed with CpG ODN 1826 followed by two i.n. doses
of the antigen admixed with CT. The final specific se-
rum IgG levels in this group were similar to mice i.n.
immunized with CT or LT and mice immunized s.c. with
CpG ODN 1826 (P > 0.05) (Fig. 1A).
Determination of the specific IgG subclass responses
revealed that mice immunized i.n. with His6MSP119-
PADRE or
 
His6MSP119 in the presence of CT or LT, elic-
ited a prevailing IgG1 response. The ratio of IgG1/IgG2c
varied from 158.5 to 501.2, with LT in both cases
(Fig.1B). The presence of CpG ODN in the vaccine for-
Fig. 1: magnitude and IgG subclasses of the antibody immune response
of mice immunized with the recombinant proteins His6MSP119-PADRE
or His6MSP119 in the presence of different adjuvant formulations. A:
C57BL/6 mice were immunized i.n or s.c. with three doses of 10 mg of
recombinant protein, two weeks apart, in the presence or absence of the
indicated adjuvants. Results are expressed as the logarithmic (Log10) anti-
body titer of each individual mouse after the third immunizing dose (n = 6).
For statistical analyses see results section; B: specific antibodies of dis-
tinct IgG subclasses were detected with serum samples harvested 2 weeks
after the third immunizing dose. Results are expressed as the mean of six
mice ± S.D. The IgG1/IgG2c ratios were indicated on the top of the figure.
mulations significantly reduced this ratio, which varied
from 2.5 (s.c. route) to 50.1 (CpG + CT, s.c./i.n immu-
nization regimen) (Fig. 1B). These results clearly dem-
onstrate the Th2 bias of the immune responses induced
by the intra-nasal immunization in the presence of CT
and LT. In contrast, CpG ODN 1826 modulates the im-
mune response toward a more balanced Th1-Th2 pattern.
The longevity of the antibody immune response was
also compared among groups of immunized C57BL/6
mice. We found that the serum IgG responses to
His6MSP119 were extremely long lived in mice immu-
nized with His6MSP119-PADRE or His6MSP119 antigens
in the presence of all tested adjuvants. No significantly
faster decay of specific antibody responses was associ-
ated to a particular adjuvant (Fig. 2).
Antibodies induced after immunization with His6
MSP119-PADRE or His6MSP119 admixed with different
adjuvants show similar affinities to the target antigen as
indicated in Fig. 3.
Fig. 2: longevity of the antibody immune responses elicited in C57BL/6
mice immunized with His6MSP119-PADRE or His6MSP119 in different
adjuvant formulations. C57BL/6 mice were immunized i.n. or s.c. with
three doses of 10 mg of the recombinant proteins, two weeks apart, in the
presence of the indicated adjuvants. Results are expressed as the mean
of six mice ± S.D. of log antibody titers detected at the indicated weeks
after the first immunizing dose.
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DISCUSSION
Our study demonstrated unequivocally that the re-
combinant proteins His6MSP119 and His6MSP119-PA-
DRE of P. vivax are highly immunogenic to C57BL/6
mice when administered through the i.n. route in the pres-
ence of the mucosal adjuvants CT or LT. These formula-
tions generated high IgG1 antibody titers that remained el-
evated even six months after the third immunization. In a
previous study, it was described that the intra-nasal immu-
nization with a recombinant protein containing the C-ter-
minal region of the P. yoelii MSP119 antigen generated pro-
tective antibodies against an experimental challenge of mice
against blood stage malaria (Hirunpetcharat et al. 1998).
Together with our data, these results may open impor-
tant perspectives for the development of an anti-malarial
vaccine using this alternative administration route.
In our earlier work, we observed that the 13-amino
acid long PADRE epitope AKFVAAWTLKAAA
(Alexander et al. 1994) significantly improved the elic-
ited antibody responses in mice immunized s.c. with vac-
cine formulations containing adjuvants other than com-
plete/incomplete Freund's adjuvant (Rosa et al. 2004).
In the present study, we found that the His6MSP119 anti-
gen performed as well as the His6MSP119-PADRE at in-
ducing high specific serum antibody titers when injected
by the i.n. route in the presence of CT or LT. These ob-
servations imply that CT and LT are endowed with strong
adjuvant effects, similarly to the effect observed with
the complete/incomplete Freund's adjuvant, and, there-
fore, do not require a strong activation of T helper cell
response. Alternatively, it is possible that the T cell and/
or B cell activation thresholds differ according the ad-
ministration route. In this regard, we recently observed
that i.n. vaccination with a recombinant protein of Try-
panosoma cruzi required B cells to prime specific CD4+
and CD8+ T cells (MM Rodrigues, unpublished results).
The fact that B cells are critical for the priming of cell-
mediated immune responses following i.n. administra-
tion of specific vaccine formulations may explain, at
least in part, the distinct performance of the CD4 PA-
DRE epitope.
The mechanisms implicated in the adjuvant activity
of CT and LT remains elusive. The two toxins are mem-
bers of the AB class bacterial toxins in which the enzy-
matically active ADP-ribosylating A subunit is respon-
sible for the toxicity while the pentameric B subunit oli-
gomer recognizes and binds to ganglioside receptors,
such as GM-1, present on the surface of different cells
types  (Lavelle et al. 2004). The inherent toxicity of these
molecules hampers their use in human trials, but the use
of the nontoxic B subunit alone or detoxified whole
molecule derivatives represent promising alternatives
for the future pre-clinical and clinical testing of these
vaccine formulations (Jakobsen et al. 2002, Holmgren
et al. 2005, reviewed by Freytag & Clements 2005,
Holmgren & Czerkinsky 2006).
Several groups have described CpG ODN 1826 as an
effective mucosal adjuvant (reviewed by Holmgren &
Czerkinsky 2006). We observed that, for our recombi-
nant proteins, CpG ODN 1826 showed less efficient
adjuvant effects than CT or LT when administered via the
i.n. route. Nevertheless, the synthetic oligonucleotides
showed an excellent adjuvant activity when administered
to mice via the s.c. route. Additionally, combination of
CpG ODN 1826 with CT resulted in similar IgG re-
sponses with reduced bias toward a Th2 immune re-
sponse pattern. Therefore, CpG ODN 1826 can be a use-
ful adjuvant alternative for the differential activation of
T helper response leading to a more balanced Th1-Th2
immune response.
In summary, our results demonstrated that strong and
specific serum IgG responses can be achieved in mice
immunized with important recombinant antigens derived
from P. vivax by the i.n. administration in the presence
of the adjuvants CT or LT. This observation may be use-
ful for the rational design of new vaccine formulations
against P. vivax malaria.
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